(Hypertension. 1999;33:402-407.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Presented in part at the 52nd Annual Fall Conference and Scientific Sessions of the American Heart Association, sponsored by American Heart Association's Council for High Blood Pressure Research, Philadelphia, Pa, September 1518, 1998.
From the Department of Cardiovascular Pharmacology (K.M.A., R.N.W.), SmithKline Beecham Pharmaceuticals, King of Prussia, Pa; and the Department of Surgery (A.D.E., W.J.K.), Duke University Medical Center, Durham, NC.
Correspondence to Dr Karen M. Anderson, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Rd, UW2510, King of Prussia, PA 19406. E-mail Karen_M_Anderson{at}SBPHRD.com
AbstractResponsiveness to ß-adrenergic stimulation is reduced in the failing human myocardium. This results principally from reduced ß-adrenergic receptor (ßAR) density, elevated ß-adrenergic receptor kinase 1 (ßARK1) levels, and functional uncoupling of remaining receptors. The temporal nature of changes in the human myocardial ß-adrenergic system relative to onset of symptomatic heart failure (HF) has been difficult to discern. A relatively new model of HF, the spontaneously hypertensive heart failure (SHHF) rat spontaneously and reproducibly develops left ventricular hypertrophy (LVH) and progresses to HF, thus enabling longitudinal studies to examine the cellular and molecular bases for hypertension-induced cardiac hypertrophy and subsequent HF. The purpose of this study was to examine age-dependent changes in the ßAR system in this model. Lean male SHHF rats at 3, 7, 14, and 20 months were compared with age-matched Sprague-Dawley (SD) control rats ([C]; 4 animals/group). At all ages the SHHF rats had elevated blood pressures and left ventricular end-diastolic pressure relative to the SD control rats (P<0.05). Compared with age-matched SD control rats, LVH was evident by 3 months in SHHF rats; 20-month-old SHHF rats had significantly greater LVH compared with the other SHHF rat groups. ß-adrenergic responsiveness (maximal heart rate to isoproterenol) was reduced only in 20-month-old SHHF rats. ßARK1 protein levels and activity were elevated at 14 months (162±10% and 195±20% C, respectively), and ßARK1 protein remained elevated at 20 months (140±14% C). In contrast, G proteincoupled receptor kinase 5, a second receptor kinase in the heart, remained unchanged at all ages. ßAR density did not change with age in the SD control rats and was similar in the SHHF rats until 20 months of age when the receptor number was reduced (30±1%). These data indicate that cardiac dysfunction is coincident with reduced ßAR density. Importantly, cardiac dysfunction was preceded by elevated ßARK1 levels and activity, thus suggesting that ßARK1 may be a precipitating factor in the transition from hypertension-induced compensatory cardiac hypertrophy to HF. Furthermore, these results indicate that the SHHF rat is a powerful model for use in examination of the mechanisms involved in alterations of ß-adrenergic signaling that occur in human HF.
Key Words: hypertension, experimental hypertrophy, cardiac heart failure receptors, adrenergic, beta kinase adenylyl cyclase rats, inbred SHR
This article has been cited by other articles:
![]() |
M. S. Hazari, N. Haykal-Coates, D. W. Winsett, D. L. Costa, and A. K. Farraj Continuous Electrocardiogram Reveals Differences in the Short-Term Cardiotoxic Response of Wistar-Kyoto and Spontaneously Hypertensive Rats to Doxorubicin Toxicol. Sci., July 1, 2009; 110(1): 224 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I. Cohn, Y. Xi, S. Pesant, D. M. Harris, T. Hyslop, B. Falkner, and A. D. Eckhart G Protein-Coupled Receptor Kinase 2 Expression and Activity Are Associated With Blood Pressure in Black Americans Hypertension, July 1, 2009; 54(1): 71 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Kelly, P. Wu, C. E. Patterson, C. Temm, and J. H. Dominguez LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1136 - F1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Dominguez, J. L. Mehta, D. Li, P. Wu, K. J. Kelly, C. S. Packer, C. Temm, E. Goss, L. Cheng, S. Zhang, et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations Am J Physiol Renal Physiol, January 1, 2008; 294(1): F110 - F119. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Penela, C. Murga, C. Ribas, A. S. Tutor, S. Peregrin, and F. Mayor Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease Cardiovasc Res, January 1, 2006; 69(1): 46 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Iaccarino, E. Barbato, E. Cipolletta, V. De Amicis, K. B. Margulies, D. Leosco, B. Trimarco, and W. J. Koch Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure Eur. Heart J., September 1, 2005; 26(17): 1752 - 1758. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, E. Sentex, H. K. Saini, D. Chapman, and N. S. Dhalla Upregulation of {beta}-adrenergic receptors in heart failure due to volume overload Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H151 - H159. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Emani, A. S. Shah, M. K. Bowman, D. C. White, S. Emani, D. D. Glower, and W. J. Koch Right ventricular targeted gene transfer of a {beta}-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 787 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Dobson, J. Fray, J. L. Leonard, and R. E. Pratt Molecular mechanisms of reduced {beta}-adrenergic signaling in the aged heart as revealed by genomic profiling Physiol Genomics, October 17, 2003; 15(2): 142 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-P. Xiao, S.-J. Zhang, K. Chakir, P. Avdonin, W. Zhu, R. A. Bond, C. W. Balke, E. G. Lakatta, and H. Cheng Enhanced Gi Signaling Selectively Negates {beta}2-Adrenergic Receptor (AR)- but Not {beta}1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts Circulation, September 30, 2003; 108(13): 1633 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hata and W. J. Koch Phosphorylation of G Protein-Coupled Receptors: GPCR Kinases in Heart Disease Mol. Interv., August 1, 2003; 3(5): 264 - 272. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kacimi and A. M. Gerdes Alterations in G Protein and MAP Kinase Signaling Pathways During Cardiac Remodeling in Hypertension and Heart Failure Hypertension, April 1, 2003; 41(4): 968 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tabbi-Anneni, C. Helies-Toussaint, D. Morin, A. Bescond-Jacquet, A. Lucien, and A. Grynberg Prevention of Heart Failure in Rats by Trimetazidine Treatment: A Consequence of Accelerated Phospholipid Turnover? J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1003 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Spyrou, S. D. Rosen, F. Fath-Ordoubadi, R. Jagathesan, R. Foale, J. S. Kooner, and P. G. Camici Myocardial beta-adrenoceptor densityone month after acute myocardial infarctionpredicts left ventricular volumes at six months J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1216 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. P. Yi, A. M. Gerdes, and F. Li Myocyte Redistribution of GRK2 and GRK5 in Hypertensive, Heart-Failure-Prone Rats Hypertension, June 1, 2002; 39(6): 1058 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Eckhart, T. Ozaki, H. Tevaearai, H. A. Rockman, and W. J. Koch Vascular-Targeted Overexpression of G Protein-Coupled Receptor Kinase-2 in Transgenic Mice Attenuates beta -Adrenergic Receptor Signaling and Increases Resting Blood Pressure Mol. Pharmacol., April 1, 2002; 61(4): 749 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Swynghedauw and D Charlemagne What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D43 - D49. [Abstract] [PDF] |
||||
![]() |
K. Leineweber, I. Heinroth-Hoffmann, K. Ponicke, G. Abraham, B. Osten, and O.-E. Brodde Cardiac {beta}-Adrenoceptor Desensitization Due to Increased {beta}-Adrenoceptor Kinase Activity in Chronic Uremia J. Am. Soc. Nephrol., January 1, 2002; 13(1): 117 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Vinge, E. Oie, Y. Andersson, H. K. Grogaard, G. O. Andersen, and H. Attramadal Myocardial distribution and regulation of GRK and beta -arrestin isoforms in congestive heart failure in rats Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2490 - H2499. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Emani, A. S. Shah, D. C. White, D. D. Glower, and W. J. Koch Right ventricular gene therapy with a {beta}-adrenergic receptor kinase inhibitor improves survival after pulmonary artery banding Ann. Thorac. Surg., November 1, 2001; 72(5): 1657 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Iaccarino, J. R. Keys, A. Rapacciuolo, K. F. Shotwell, R. J. Lefkowitz, H. A. Rockman, and W. J. Koch Regulation of myocardial {beta}ARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing {alpha}1B-adrenergic receptors J. Am. Coll. Cardiol., August 1, 2001; 38(2): 534 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Iaccarino, E. Barbato, E. Cipolleta, A. Esposito, A. Fiorillo, W. J. Koch, and B. Trimarco Cardiac {beta}ARK1 Upregulation Induced by Chronic Salt Deprivation in Rats Hypertension, August 1, 2001; 38(2): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-E. Laurent, R. Cardinal, G. Rousseau, M. Vermeulen, C. Bouchard, M. Wilkinson, J. A. Armour, and M. Bouvier Functional desensitization to isoproterenol without reducing cAMP production in canine failing cardiocytes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2001; 280(2): R355 - R364. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nagata, C. Communal, C. C. Lim, M. Jain, T. M. Suter, F. R. Eberli, N. Satoh, W. S. Colucci, C. S. Apstein, and R. Liao Altered beta -adrenergic signal transduction in nonfailing hypertrophied myocytes from Dahl salt-sensitive rats Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2502 - H2508. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. White, J. A. Hata, A. S. Shah, D. D. Glower, R. J. Lefkowitz, and W. J. Koch Preservation of myocardial beta -adrenergic receptor signaling delays the development of heart failure after myocardial infarction PNAS, May 9, 2000; 97(10): 5428 - 5433. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dodic, C. Samuel, K. Moritz, E. M. Wintour, J. Morgan, L. Grigg, and J. Wong Impaired Cardiac Functional Reserve and Left Ventricular Hypertrophy in Adult Sheep After Prenatal Dexamethasone Exposure Circ. Res., September 28, 2001; 89(7): 623 - 629. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |